Biomarkers of therapeutic response to BCL2 antagonists in cancer.
about
Potential mechanisms of resistance to venetoclax and strategies to circumvent it.Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB/non-GCB by immunohistochemistry is still a robust and feasible marker.Functional oncogene signatures guide rationally designed combination therapies to synergistically induce breast cancer cell death.Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.rno-miR-665 targets BCL2L1 (Bcl-xl) and increases vulnerability to propofol in developing astrocytes.
P2860
Biomarkers of therapeutic response to BCL2 antagonists in cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Biomarkers of therapeutic response to BCL2 antagonists in cancer.
@en
type
label
Biomarkers of therapeutic response to BCL2 antagonists in cancer.
@en
prefLabel
Biomarkers of therapeutic response to BCL2 antagonists in cancer.
@en
P2093
P2860
P1476
Biomarkers of therapeutic response to BCL2 antagonists in cancer.
@en
P2093
Brenda Chyla
Haichao Zhang
Lloyd T Lam
P2860
P2888
P304
P356
10.1007/S40291-012-0003-6
P577
2012-12-01T00:00:00Z
P6179
1008529944